Medical Devices and Combination Products - Precision Medicines and Diagnostics
The future treatment of patients will rely increasingly on multiple products which are working together to achieve an enhanced patient experience. Consequently, the regulatory framework which has historically been focused on individual product types (Medical Devices and Medicinal Products) needs to become more holistic. Simultaneously, while there is a focus on innovative precision agents, the combination with novel companion diagnostics creates significant impact and becomes an important point of collaboration between pharma and medical devices.
Who is This Track Designed For?
This track and associated sessions are designed for professionals involved, interested or curious about Medical Devices, Combination Products, Precision Medicine and Diagnostics.
The online program is now available. Explore the rich content we offer across 10 thought leadership tracks.
Novo Nordisk, Denmark
Senior Director Regulatory Affairs
AstraZeneca, United Kingdom
Hear From Our Speakers
Hear from Tim Chesworth, Senior Director Regulatory Affairs at AstraZeneca UK, why you should join DIA Europe 2023.
DIA Europe 2023 Highlights
It will provide updates on key developments on the GCP Renovation (ICH E6, ICH E8), Clinical Trial Regulation, the Clinical Trial Information System, data submission, transparency, navigating ethical approval, study design in the digital age, innovative clinical trial designs (umbrella and platform trials, patient centricity), digital tools in development and other hot topics. It should be a must-attend for optimising development programmes and identifying cost savings through efficiency and innovation.